Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors

NCT00777504 Phase 4 UNKNOWN

The purpose of this study is to determine if and how often an unexpected fast increase of disease and complaints shows after stopping the anti-angiogenetic therapy

Details

Lead sponsor	Radboud University Medical Center
Phase	Phase 4
Status	UNKNOWN
Enrolment	30
Start date	2008-10
Completion	2012-04

Conditions

• Renal Cell Carcinoma
• Gastrointestinal Stromal Tumor

Interventions

• usage oral angiogenesis inhibitor
• stop oral angiogenesis inhibitor

Primary outcomes

• Signs of progressive disease on CT-scan, DCE-MRI or Avastin scan — 4 weeks

Countries

Netherlands